On December 19, 2017, Voretigene neparvovec-rzyl (VN, LUXTURNA, Spark Therapeutics, Philadelphia, PA, USA) was approved by the Food and Drug Administration (FDA) for the treatment of RPE65-associated IRDs, becoming the first FDA-approved gene therapy for a genetic disease [5]. Here, RPE65 is linked to respiratory distress syndrome in premature infants.